Tandem Diabetes Care Issued Patent Related to Automated Insulin Delivery Technology

Tandem Diabetes Care Inc., a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, has been issued U.S. Patent No. 9,833,177, titled “Insulin Pump Based Expert System.” It refers to a pump system that suspends, among other operations, the delivery of insulin if a user’s sensor glucose data reaches or falls below an acceptable level, alerts the user and recommends that the user initiate a blood glucose measurement.

This patent is part of the portfolio of intellectual property acquired by the company from Smiths Medical ASD Inc. in 2013.
 
“This important patent directly relates to reducing patient risk for hypoglycemia, which is the most valued aspect of automated insulin delivery in our market research,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “There is increasing industry focus on automating insulin delivery and the benefits it may provide people with diabetes, and we believe this new patent substantially strengthens Tandem’s already robust portfolio of intellectual property in support of these efforts.”
 
This latest patent is scheduled to expire in December 2028. The company has a related U.S. continuation application on file.
 
Tandem Diabetes Care now has 56 issued U.S. patents and 52 pending U.S. patent applications. In addition, the company has, and is seeking, patent protection for proprietary technologies in other countries throughout the world.
 
Tandem Diabetes Care Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The company takes a user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements. The t:slim X2 is the only insulin pump available with Dexcom G5 Mobile continuous glucose monitoring (CGM) integration. Tandem is based in San Diego, Calif.
 
Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom Inc.